Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT6TU05)

• DTT Name: WWP2 messenger RNA (WWP2 mRNA)
• Synonyms: WW domaincontaining protein 2 (mRNA); WW domain-containing protein 2 (mRNA); NEDD4like E3 ubiquitinprotein ligaseWWP2 (mRNA); HECT-type E3 ubiquitin transferase WWP2 (mRNA); Atrophin1interacting protein 2 (mRNA); Atrophin-1-interacting protein 2 (mRNA); AIP2 (mRNA)
• Gene Name: WWP2
• DTT Type: Literature-reported target; [1]
• BioChemical Class: mRNA target
• UniProt ID: WWP2_HUMAN
• TTD ID: T73502
• EC Number: EC 2.3.2.26
• Sequence:
  MASASSSRAGVALPFEKSQLTLKVVSAKPKVHNRQPRINSYVEVAVDGLPSETKKTGKRI
  GSSELLWNEIIILNVTAQSHLDLKVWSCHTLRNELLGTASVNLSNVLKNNGGKMENMQLT
  LNLQTENKGSVVSGGELTIFLDGPTVDLGNVPNGSALTDGSQLPSRDSSGTAVAPENRHQ
  PPSTNCFGGRSRTHRHSGASARTTPATGEQSPGARSRHRQPVKNSGHSGLANGTVNDEPT
  TATDPEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEPSTSGTQQLPAAAQAPD
  ALPAGWEQRELPNGRVYYVDHNTKTTTWERPLPPGWEKRTDPRGRFYYVDHNTRTTTWQR
  PTAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSSSASTDHDPLGPLPPGWEKRQDNGRV
  YYVNHNTRTTQWEDPRTQGMIQEPALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFE
  SGTKQGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTLFEDSFQQIMNMKPYDL
  RRRLYIIMRGEEGLDYGGIAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPD
  HLTYFRFIGRFIAMALYHGKFIDTGFTLPFYKRMLNKRPTLKDLESIDPEFYNSIVWIKE
  NNLEECGLELYFIQDMEILGKVTTHELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQ
  TKAFLDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKSTIYRHYTKNSKQIQWFW
  QVVKEMDNEKRIRLLQFVTGTCRLPVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFN
  RLDLPPYKSYEQLREKLLYAIEETEGFGQE
• Function: Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
• KEGG Pathway: Ubiquitin mediated proteolysis (hsa04120)
• Reactome Pathway:
  RHOQ GTPase cycle (R-HSA-9013406)
  RHOJ GTPase cycle (R-HSA-9013409)
  RHOU GTPase cycle (R-HSA-9013420)
  NOTCH3 Activation and Transmission of Signal to the Nucleus (R-HSA-9013507)
  Regulation of PTEN stability and activity (R-HSA-8948751)

Molecular Interaction Atlas (MIA) of This DTT

11 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 103669	DM3TIJD	Discovery agent	N.A.	Investigative	[1]
ISIS 103671	DMF9JAH	Discovery agent	N.A.	Investigative	[1]
ISIS 103701	DMQ48YZ	Discovery agent	N.A.	Investigative	[1]
ISIS 103708	DMLVPOA	Discovery agent	N.A.	Investigative	[1]
ISIS 103736	DMKI6JF	Discovery agent	N.A.	Investigative	[1]
ISIS 103747	DM7DOY3	Discovery agent	N.A.	Investigative	[1]
ISIS 103752	DMBZVW0	Discovery agent	N.A.	Investigative	[1]
ISIS 103771	DM8HDW6	Discovery agent	N.A.	Investigative	[1]
ISIS 103803	DMVL8O0	Discovery agent	N.A.	Investigative	[1]
ISIS 103806	DMA0D8I	Discovery agent	N.A.	Investigative	[1]
ISIS 103819	DMFQ10R	Discovery agent	N.A.	Investigative	[1]

References

• [1] US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.